Scottish architect Allan Murray has been appointed to lead an ambitious project to expand the development of the Edinburgh BioQuarter in Scotland.
Home to the Scottish Centre for Regenerative Medicine (SCRM), the quarter is on schedule to open towards the end of this year. Work on the £60m building began in December 2008 and, when complete, it will provide a facility for 260 researchers looking at how to apply stem cell research to conditions such as Parkinson’s disease, diabetes and heart disease.
In early 2012, the next phase – known as Nine, The BioQuarter – will open, offering office and lab space dedicated to startups and established life science companies. The aim is to position Edinburgh as one of the world’s top 10 hubs for life sciences research and development.
“This is another exciting milestone in the development of Edinburgh BioQuarter,” said David Leven, business infrastructure team leader at Scottish Enterprise. “It is vital that Scotland has a business environment that supports the forecast growth of our life sciences sector and can compete over the long term with other international locations for investment.
Edinburgh has one of the largest concentrations of life scientists in the world and the site is next to a research hospital with a clinical trials unit, the University of Edinburgh’s teaching and research facilities, basic research scientists and biotechnology companies.
“I think that’s a unique combination with huge potential for translational research but also the use of stem cells in drug discovery and development work. It will be a unique resource in the UK”, said Professor Sir Ian Wilmut, creator of the cloned sheep Dolly and resident of Edinburgh.
The £600 m project is a collaboration between Scottish Enterprise, the University of Edinburgh, NHS Lothian and the world’s leading life science property specialist, Alexandria Real Estate Equities, Inc. BioQuarter has engaged a team of experienced life science business professionals and is preparing its first companies for deals with investors, as well as negotiating the first major collaborative agreements with international bio-pharmaceutical companies.
For details visit www.edinburghbioquarter.com